Gwenn Hansen - Feb 13, 2024 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
Stock symbol
NRIX
Transactions as of
Feb 13, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 07:23 AM
Previous filing
Jan 30, 2024
Next filing
Apr 30, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +150K $0.00 150K Feb 13, 2024 Common Stock 150K $8.72 Direct F1
transaction NRIX Restricted Stock Units Award $0 +45K $0.00 45K Feb 13, 2024 Common Stock 45K $0.00 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
F4 RSUs do not expire; they either vest or are canceled prior to the vest date.